Necessities for a Clinical Islet Program
For more than two decades we have been refining advances in islet cell transplantation as a clinical therapy for patients suffering from type 1 diabetes. A great deal of effort has gone to making this a viable therapy for a broader range of patients with type 1 diabetes. Clinical results have progressively improved, demonstrating clinical outcomes on par with other organ transplants, specifically in terms of insulin independence, graft and patient survival. We are now at the point where islet cell transplantation, in the form of allotransplantation, has become accepted as a clinical therapy in adult patients affected by type 1 diabetes, in particular those suffering from severe hypoglycaemic unawareness. This chapter provides an overview on how this has been undertaken over the years to provide outcomes on par with other organ transplantation results. In particular this chapter focuses on the processes and facilities that are required to establish a clinical islet isolation and transplantation program. It also outlines the very important underpinning processes of selection of the organ donor for islet isolation, the processes of organ donor operation and preservation of the pancreas by various means and the ideal ways to best improve outcomes for human islet cell isolation. Providing these more optimal conditions we can underpin the isolation processes to provide islets for transplantation and as such a safe, effective and feasible therapeutic option for an increasing number of patients suffering from type 1 diabetes with severe hypoglycaemic unawareness.
KeywordsDiabetes Insulin Islet Islet cell Islet cell allotransplantation Islet cell autotransplantation Islet cell isolation Islet equivalent (IEQ), type 1 diabetes (T1D)
Body mass index
Cold ischaemic time
Connaught Medical Research Laboratories
Islet cell isolation, islet equivalent
Islet equivalents per gram
Mixed treatment comparison
Quality-adjusted life years
Simultaneous pancreas and kidney
Type 1 diabetes
University of Wisconsin solution
- 5.Greenwald MA, Kuehnert MJ, Fishman JA. Infectious disease transmission during organ and tissue transplantation. Emerg Infect Dis. 2012;18(8):e1.Google Scholar
- 7.Kovacs CS, van Duin D, Guedes de Morais A, Gonzalez BE, Avery RA, Mawhorter SD, Brizendine KD, Cober E, Miranda C, Shrestha RK, Teixeira L, Mossad SB. Selecting suitable solid organ transplant donors: reducing the risk of donor-transmitted infections. World J Transplant. 2014;4(2):43–56.Google Scholar
- 9.Shahrestani S, WA, Lam VW, Yuen L, Ryan B, Pleass HC, Hawthorne WJ. Outcomes from pancreatic transplantation in donation after cardiac death: a systematic review and meta-analysis. Transplantation. 2016; Epub Date 2016/03/08, PMCID: 26950713. doi: 10.1097/TP.0000000000001084
- 14.U.S. Department of Health and Human Services FDA. International standard ISO 14644 and associated controlled environments [Available from: http://drug.fda.moph.go.th/drug/zone_gmp/files/GMP2549_2/Aug2106/7.ISO14644.pdf.
- 18.Moassesfar S MU, Frassetto LA, Szot GL, Tavakol M, Stock PG, Posselt AM. A comparative analysis of the safety, efficacy, and cost of islet versus pancreas transplantation in nonuremic patients with type 1 diabetes. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2015.Google Scholar
- 20.ANZDATA. Australia and New Zealand dialysis and transplant registry 38th report, chapter 2: prevalence of end stage kidney disease. 2016 [Available from: http://www.anzdata.org.au.
- 23.Balamurugan AN, Naziruddin B, Lockridge A, Tiwari M, Loganathan G, Takita M, et al. Islet product characteristics and factors related to successful human islet transplantation from the Collaborative Islet Transplant Registry (CITR) 1999–2010. Am J Transplant : Off J Am Soc Transplant Am Soc Transplant Surg. 2014;14(11):2595–606.CrossRefGoogle Scholar
- 25.Al-Adra DP, Gill RS, Imes S, O’Gorman D, Kin T, Axford SJ, Shi X, Senior PA, Shapiro AM. Single-donor islet transplantation and long-term insulin independence in select patients with type 1 diabetes mellitus. Transplantation. 2014;98(9):1007–12.
- 27.Thompson DM, Meloche M, Ao Z, Paty B, Keown P, Shapiro RJ, Ho S, Worsley D, Fung M, Meneilly G, Begg I, Al Mehthel M, Kondi J, Harris C, Fensom B, Kozak SE, Tong SO, Trinh M, Warnock G. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. Transplantation. 2011;91(3):373–8.PubMedCrossRefGoogle Scholar
- 30.Hays R. Transplant community looks for ways to incentivize living organ donation. Nephrol News Issues. 2016;30(1:24):26–7.Google Scholar
- 34.Basta G, Montanucci P, Calafiore R. Islet transplantation versus stem cells for the cell therapy of type 1 diabetes mellitus. Minerva endocrinologica. 2015.Google Scholar
- 39.Cardillo M, Nano R, de Fazio N, Melzi R, Drago F, Mercalli A, et al. The allocation of pancreas allografts on donor age and duration of intensive care unit stay: the experience of the North Italy Transplant program. Transplant Int : Off J Eur Soc Organ Transplant. 2014;27(4):353–61.CrossRefGoogle Scholar
- 45.Thwaites SE, Gurung B, Yao J, Kable K, Robertson P, Ryan BJ, Lam VW, Pleass HC, Chapman JR, Hawthorne WJ, Allen RD. Excellent outcomes of simultaneous pancreas kidney transplantation in patients from rural and urban Australia: a national service experience. Transplantation. 2012;94(12):1230–5.PubMedCrossRefGoogle Scholar
- 51.Hameed A, Yu T, Yuen L, Lam V, Ryan B, Allen R, et al. Use of the harmonic scalpel in cold phase recovery of the pancreas for transplantation: the Westmead technique. Transpl Int. 2016.Google Scholar
- 52.Romanescu D, Gangone E, Boeti MP, Zamfir R, Dima SO, Popescu I. Technical aspects involved in the harvesting and preservation of the pancreas used for pancreatic islet allotransplantation. Chirurgia (Bucur). 2013;108(3):372–80.Google Scholar
- 53.Cao YS, S., Chew HC, Crawford M, Macdonald PS, Laurence J, Hawthorne WJ, et al. Donation after circulatory death for liver transplantation: a meta-analysis on the location of life support withdrawal affecting outcomes. Transplant. 2016.Google Scholar
- 56.Niclauss N, Wojtusciszyn A, Morel P, Demuylder-Mischler S, Brault C, Parnaud G, et al. Comparative impact on islet isolation and transplant outcome of the preservation solutions Institut Georges Lopez-1, University of Wisconsin, and Celsior. Transplantation. 2012;93(7):703–8.PubMedCrossRefGoogle Scholar
- 65.Kim A, Kilimnik G, Guo C, Sung J, Jo J, Periwal V, et al. Computer-assisted large-scale visualization and quantification of pancreatic islet mass, size distribution and architecture. J Visualized Exp: JoVE. 2011(49).Google Scholar
- 78.Bruni A, Gala-Lopez B, Pepper AR, Abualhassan NS, Shapiro AJ. Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges. Diabetes Metab Syndr Obes : Targets Ther. 2014;7:211–23.Google Scholar